Literature DB >> 11135084

Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages.

G S Hill1, M Delahousse, D Nochy, P Rémy, F Mignon, J P Méry, J Bariéty.   

Abstract

BACKGROUND: A new Biopsy Index containing the Glomerular Activity (GAI), Tubulointerstitial Activity (TIAI), Chronic Lesion (CLI), and Immunofluorescence (IFI) indices was developed, showing better correlations with clinical and outcome parameters than the National Institutes of Health Activity and Chronicity Indices (AI and CI) in lupus nephritis. This report examines the ability of these indices and individual morphologic variables to predict doubling of serum creatinine (SCr; CRX2).
METHODS: Renal biopsies from 71 patients with lupus nephritis with an initial biopsy (Bx1) and systematic control biopsy (Bx2) after six months of therapy were studied. Kaplan-Meier survival curves were developed for each index and morphologic variable at each biopsy. A subset of 30 biopsies was stained with the macrophage marker PGM1.
RESULTS: At Bx1, only the TIAI and the quantity of C3 and vascular staining on IF were predictive of CRX2. At Bx2, particularly predictive of CRX2 were the GAI, IFI, Biopsy Index, and BxInfl, a composite variable comprised of all of the inflammatory variables. Among individual variables, glomerular and tubular macrophages correlated the best with clinical and outcome parameters. Crescents and karyorrhexis/fibrinoid necrosis also correlated with outcome. Neither the NIH CI or our CLI, nor the TIAI correlated with outcome. In 30 biopsies stained with PGM1, PGM1+ cells correlated well with glomerular and tubular macrophages identified on routine stains and showed even better correlations with SCr, proteinuria, and progression to renal insufficiency than the latter. A diffuse membranoproliferative (MPGN) pattern was seen in seven patients at Bx1. In four of the seven patients, MPGN disappeared with therapy, and all finished with normal renal function. However, among the three patients in whom MPGN persisted and eight patients in whom MPGN, focal or diffuse, appeared under therapy, six reached end-stage renal disease, and a seventh died with marked renal insufficiency.
CONCLUSIONS: The biopsy index and its components correlate modestly with CRX2 at Bx1, but strongly at Bx2, particularly IFI, BxInfl, and glomerular and tubular macrophages. Stains for macrophage markers form a valuable adjunct in interpretation of renal biopsies in systemic lupus erythematosus (SLE). MPGN features do not have an ominous significance at Bx1, but their persistence or appearance under therapy are associated with poor outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135084     DOI: 10.1046/j.1523-1755.2001.00492.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  89 in total

Review 1.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

2.  Critical Role of Macrophage FcγR Signaling and Reactive Oxygen Species in Alloantibody-Mediated Hepatocyte Rejection.

Authors:  Jason M Zimmerer; Xin L Liu; Alecia Blaszczak; Christina L Avila; Thomas A Pham; Robert T Warren; Ginny L Bumgardner
Journal:  J Immunol       Date:  2018-11-05       Impact factor: 5.422

3.  Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis.

Authors:  Lena Schiffer; Ramalingam Bethunaickan; Meera Ramanujam; Weiqing Huang; Mario Schiffer; Haiou Tao; Michael P Madaio; Michael M Madaio; Erwin P Bottinger; Anne Davidson
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

Review 4.  Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging.

Authors:  Joshua M Thurman; Natalie J Serkova
Journal:  Adv Chronic Kidney Dis       Date:  2013-11       Impact factor: 3.620

5.  Glomerular disease: Lupus nephritis treatment: are we beyond cyclophosphamide?

Authors:  Brad H Rovin
Journal:  Nat Rev Nephrol       Date:  2009-09       Impact factor: 28.314

Review 6.  B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.

Authors:  R John Looney
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 7.  Immunopathology of lupus nephritis.

Authors:  Hans-Joachim Anders; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

8.  CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.

Authors:  Samantha A Chalmers; Jing Wen; Justine Shum; Jessica Doerner; Leal Herlitz; Chaim Putterman
Journal:  Clin Immunol       Date:  2016-08-26       Impact factor: 3.969

9.  Cytokine-induced monocyte characteristics in SLE.

Authors:  Zhe Zhang; Kelly Maurer; Juan C Perin; Li Song; Kathleen E Sullivan
Journal:  J Biomed Biotechnol       Date:  2010-06-24

10.  Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes.

Authors:  Z Zhang; L Song; K Maurer; M A Petri; K E Sullivan
Journal:  Genes Immun       Date:  2009-08-27       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.